Yahoo

HIV drug's Medicare costs under negotiation

Add Yahoo as a preferred source to see more of our stories on Google. bottle of HIV suppressing drug Biktarvy The federal government is negotiating lower Medicare prices for a popular once-daily pill ...

FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients

The new pill is also aimed at people who are doing well on a single-tablet regimen, including Biktarvy, and want to switch to a new treatment.
Hosted on MSN

Gilead Resolves Patent Litigations for HIV Treatment Biktarvy

Gilead Sciences, Inc., GILD announced that it has entered into settlement agreements to resolve the patent litigations with a few generic manufacturers who were looking to market generic versions of ...
Law360

Gilead Gets HIV Generic Drugs Barred From Market Until 2036

Law360 (October 6, 2025, 7:05 PM EDT) -- Gilead Sciences Inc. said Monday it is keeping generic forms of its HIV treatment Biktarvy off of the market until 2036 following a series of settlements with ...

Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances

Gilead Sciences (NASDAQ:GILD) executives outlined plans to expand the company’s HIV prevention and treatment franchises while ...
Morningstar%2c Inc.

Gilead: Incorporating Longer Biktarvy Runway

On Oct. 6, Gilead Sciences GILD announced a settlement with three generic manufacturers, securing an agreement for them not to launch a generic version of the firm’s HIV drug Biktarvy in the United ...
Medical Daily

Once-Weekly HIV Pill Matches Daily Treatment as Experts Explain Why Treatment Adherence Saves Lives

More than 500,000 Medicare enrollees signed up for the $50 GLP-1 Bridge in two months what it means for eligibility, costs, and coverage after 2027. New Public Charge Rule Takes Effect Friday, Letting ...
Hosted on MSN

ViiV Healthcare’s two-drug regimen as good as Biktarvy, study finds

ViiV Healthcare’s two-drug regimen for HIV treatment is as effective as Gilead’s Biktarvy in treatment-naïve patients, as per findings from a Phase IIIb trial ...
Reuters

Merck's oral HIV treatment non-inferior to Gilead's Biktarvy in late-stage trial

Nov 19 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' (GILD.O), opens new tab top-selling drug Biktarvy ...

Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth

CFO Andy Dickinson told attendees at the Cantor Global Healthcare Conference that the company sees continued growth ...
FiercePharma

Gilead's single-tablet HIV combo of bictegravir, lenacapavir passes another late-stage test on way to filings

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead toward regulatory filings for the novel HIV regimen. In Gilead's ...
Morningstar%2c Inc.

ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV

Positive Week 48 data from the phase IIIb VOGUE study reinforce Dovato as an effective treatment option with fewer medicines than Biktarvy, across diverse populations Findings build on 10 years of ...